Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis

Acta Dermato-Venereologica

Volumn 85, Issue 5, 2005, Pages 409-413

  Mazzotti, Eva ^a   Barbaranelli, Claudio ^b   Picardi, Angelo ^a   Abeni, Damiano ^a   Pasquini, Paolo ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Factor analysis; Item response theory; Questionnaire; Skin diseases

Indexed keywords

ADULT; AGED; ARTICLE; DISABILITY; EMOTION; FACTORIAL ANALYSIS; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; SKIN DISEASE; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; PSORIASIS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS;

EID: 25144519281     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.1080/00015550510032832     Document Type: Article

References (34)

1. deArruda LH, De Moraes AP. The impact of psoriasis on quality of life. Br J Dermatol 2001; 144 (Suppl 58): 33-36.
2. Finlay AY. Quality of life assessments in dermatology. Semin Cutan Med Surg 1998; 17: 291-296.
3. Kent G, Al'Abadic M. Psychologic effects of vitiligo: a critical incident analysis. J Am Acad Dermatol 1996; 35: 895-898.
4. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life. Arch Dermatol 2001; 137: 280-284.
5. McKenna KE, Stern RS. The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. J Am Acad Dermatol 1997; 36: 388-394.
6. Porter JR, Beuf AH, Lerner AB, Nordlund JJ. The effect of vitiligo on sexual relationships. J Am Acad Dermatol 1990; 22: 221-222.
7. Rapp SR, Exum ML, Reboussin DM, Feldman SR, Fleischer A, Clark A. The physical, psychological and social impact of psoriasis. J Health Psychol 1997; 2: 525-537.
8. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407.
9. Wells PA, Willmoth T, Russell RJ. Does fortune favor the bald? Psychological correlates of hair loss in males. Br J Psychol 1995; 86: 337-344.
10. Anderson RT, Rajagopalan R. Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol 1997; 37: 41-50.
11. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CEM. Quality of life measures in psoriasis: a critical appraisal of their quality. J Clin Pharm Ther 1998; 23: 391-398.
12. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality of life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 1433-1440.
13. Finlay AY. Quality of life measurement in dermatology: a practical guide. Br J Dermatol 1997; 136: 305-314.
14. Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol 1990; 123: 751-756.
15. Gupta MA, Gupta AK. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol 1995; 75: 240-243.
16. Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of life scales - measure of impact of skin diseases. Br J Dermatol 1997; 136: 202-206.
17. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
18. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Invest Dermatol Symp Proc 2004; 9: 169-180.
19. Hahn HB, Melfi CA, Chuang TY, Lewis CW, Gonin R, Hanna MP, et al. Use of the Dermatology Life Quality Index (DLQI) in a midwestern US urban clinic. J Am Acad Dermatol 2001; 45: 44-48.
20. Badia X, Mascaro JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. Br J Dermatol 1999; 141: 698-702.
21. Mørk C, Wahl A, Mourn T. The Norwegian version of the dermatology life quality index: a study of validity and reliability in psoriatics. Acta Derm Venereol 2002; 82: 347-351.
22. Zachariae R, Zachariae C, Ibsen H, Mortensen JT, Wulf HC. Dermatology Life Quality Index: data from Danish inpatients and outpatients. Acta Derm Venereol 2000; 80: 272-276.
23. Mazzotti E, Picardi A, Sampogna F, Sera F, Pasquini P, Abeni D. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol 2003; 149: 318-322.
24. Abeni D, Picardi A, Pasquini P, Melchi CF, Chren MM. Further evidence of the validity and reliability of Skindex-29: an Italian study on 2242 outpatients. Dermatology 2002; 204: 43-49.
25. Fredriksson T, Petterson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
26. Marks R, Barton S, Shuttleworth D, Finlay AY. Assessment of disease progress in psoriasis. Arch Dermatol 1989; 125: 235-240.
27. Ashcroft DM, Li Wan Po A, Williams HG, Griffiths CEM. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999; 141: 185-191.
28. Muthén L, Muthén B. Mplus user's guide. Los Angeles, CA: Muthen & Muthen, 1998.
29. Muthén B. Contribution to factor analysis of dichotomous variables. Psychometrika 1978; 43: 551-560.
30. Andersson CG, Christoffersson A, Muthén B. FADIV. A computer program for factor analysis of dichotomized variables. Research Report 74-1. Uppsala: Uppsala University Statistics Department, 1974.
31. Hattie JA. Methodology review: assessing unidimensionality of tests and items. Applied Psychological Measurement 1985; 9: 139-164.
32. Joreskog K, Sorbom D. Lisrel 8: user's reference guide. Chicago: Scientific Software International, 1999.
33. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281-285.
34. Finlay AY, Salek MS, Khan GK, Luscombe D, Allen R, Berth-Jones J, et al. Quality of life improvement in cyclosporin treated atopic dermatitis patients: a double-blind cross-over study. Br J Dermatol 1991; 125 (Suppl 38): 16.